Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

• Nadine Kutsch,
• Christian Pallasch,
• Thomas Decker,
• Holger Hebart,
• Kai Uwe Chow,
• Ullrich Graeven,
• Jens Kisro,
• Alexander Kroeber,
• Eugen Tausch,
• Kirsten Fischer,
• Anna-Maria Fink,
• Clemens-Martin Wendtner,
• Matthias Ritgen,
• Stephan Stilgenbauer,
• Danjie Zhang,
• Biao Li,
• Juliane M. Jürgensmeier,
• Nishanthan Rajakumaraswamy,
• Pankaj Bhargava,
• Michael Hallek,
• Barbara Eichhorst

Affiliations

Nadine Kutsch

1 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany

Christian Pallasch

2 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Germany

Thomas Decker

3 Onkologie Ravensburg, Ravensburg, Germany

Holger Hebart

4 Clinics Ostalb, Stauferklinikum, Mutlangen, Germany

Kai Uwe Chow

5 Ambulantes Krebszentrum, Frankfurt, Germany

Ullrich Graeven

6 Klinik für Hämatologie, Onkologie und Gastroenterologie, Kliniken Maria Hilf GmbH, Mönchengladbach, Germany

Jens Kisro

7 Luebecker Onkologische Schwerpunktpraxis, Luebeck, Germany

Alexander Kroeber

8 Überörtliche Berufsausübungsgemeinschaft, Regensburg, Germany

Eugen Tausch

9 Department of Internal Medicine III, Ulm University, Germany

Kirsten Fischer

1 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany

Anna-Maria Fink

1 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany

Clemens-Martin Wendtner

10 Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilians-University, Munich, Germany

Matthias Ritgen

11 Department of Medicine II, University of Schleswig-Holstein, Kiel, Germany

Stephan Stilgenbauer

9 Department of Internal Medicine III, Ulm University, Germany

Danjie Zhang

12 Gilead Sciences, Inc., Foster City, CA, USA

Biao Li

12 Gilead Sciences, Inc., Foster City, CA, USA

Juliane M. Jürgensmeier

12 Gilead Sciences, Inc., Foster City, CA, USA

Nishanthan Rajakumaraswamy

12 Gilead Sciences, Inc., Foster City, CA, USA

Pankaj Bhargava

12 Gilead Sciences, Inc., Foster City, CA, USA

Michael Hallek

1 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany

Barbara Eichhorst

1 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany